订阅小程序
旧版功能

Efficacy and Safety of MIL60 Compared with Bevacizumab in Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer: a Phase 3 Randomized, Double-Blind Study

Rui Wan,Xiaorong Dong,Qun Chen,Yan Yu,Shujun Yang,Xiaochun Zhang,Guojun Zhang,Yueyin Pan,Sanyuan Sun,Chengzhi Zhou,Wei Hong,Hui Zhao,Lei Yang,Linian Huang,Rong Wu,Aimin Zang,Rui Ma,Lin Wu,Dongqing Lv,Xiuhua Fu,Jianguo Han,Wenxin Li,Jianchun Duan,Kai Wang,Ou Jiang,Yinglan Chen,Zhongliang Guo,Hongjun Gao,Juyi Wen,Shubin Wang,Enfeng Zhao,Gaofeng Li,Lu Yue,Li Liang,Aiping Zeng,Xiaoshan Wang,Yuxi Zhu,Hongming Pan,Zhaoxia Dai,Weineng Feng,Guofang Zhao, Chuan Lin,Chong Li,Na Li,Yangyi Bao,Yinyin Li,Yanjun Su,Min Zhao,Haohui Fang, Yulong Zhu,Yu Zhang,Lieming Ding, Yang Wang,Xiaobin Yuan,Jie Wang

ECLINICALMEDICINE（2021）

引用 10|浏览51
关键词
MIL60,biosimilar,bevacizumab,equivalence,non-squamous NSCLC
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要